These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29895542)

  • 1. Persistent elevation of carcinoembryonic antigen as first presentation of a medullary thyroid carcinoma.
    Martins A; Gonçalves A; Almeida T; Midões A
    BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29895542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
    Chen SW; Chen YK
    World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
    Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
    J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
    Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
    J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medullary thyroid carcinoma].
    Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
    Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
    Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
    BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin-negative medullary thyroid carcinoma: the 'triple-negative' phenotype.
    Murphy DC; Johnson SJ; Aspinall S
    Ann R Coll Surg Engl; 2020 Mar; 102(3):e63-e66. PubMed ID: 31841033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
    Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
    J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of medullary thyroid cancer in the prediction of cure after thyroidectomy.
    Nien FJ; Chang TC
    J Formos Med Assoc; 2015 Sep; 114(9):793-4. PubMed ID: 23906686
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
    Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
    Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature.
    Appetecchia M; Barnabei A; Pompeo V; Sentinelli S; Baldelli R; Corsello SM; Torino F
    BMC Endocr Disord; 2014 Oct; 14():84. PubMed ID: 25306429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Challenges of Medullary Thyroid Carcinoma.
    Leimbach RD; Hoang TD; Shakir MKM
    Oncology; 2021; 99(7):422-432. PubMed ID: 33878761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
    Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
    Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain metastasis from calcitonin-negative medullary thyroid carcinoma.
    Baptista PF; Fonseca LCM; Carvalho AFC; Silva SNVD; Freitas CRO
    Ann Endocrinol (Paris); 2022 Aug; 83(4):258-260. PubMed ID: 35537523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rising CEA levels in a patient with colon carcinoma: metachronous medullary thyroid cancer.
    Göksu SS; Göksu UA; Gündüz S; Coskun HS
    Int J Biol Markers; 2014 Jun; 29(2):e184-6. PubMed ID: 24425322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?
    Gambardella C; Offi C; Patrone R; Clarizia G; Mauriello C; Tartaglia E; Di Capua F; Di Martino S; Romano RM; Fiore L; Conzo A; Conzo G; Docimo G
    BMC Endocr Disord; 2019 May; 19(Suppl 1):45. PubMed ID: 31142313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
    Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
    Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.